8.3 Chronic GI & Malabsorption: Pediatric GERD, Celiac Disease & Inflammatory Bowel Disease

Chronic GI & Malabsorption: Pediatric GERD, Celiac Disease & Inflammatory Bowel Disease

Quick Overview: Chronic pediatric gastrointestinal disorders encompass a broad spectrum ranging from physiological maturational delays to severe lifelong autoimmune and inflammatory processes. Differentiating physiological reflux ('happy spitters') from pathological gastroesophageal reflux disease (GERD) prevents unnecessary pharmacotherapy. Celiac disease represents a systemic autoimmune enteropathy triggered by dietary gluten, requiring meticulous lifelong elimination. Pediatric inflammatory bowel disease (IBD)—comprising Crohn disease and ulcerative colitis—presents unique developmental challenges, including profound linear growth failure and delayed puberty, demanding aggressive nutritional therapy and targeted biologic agents.

---

1. Pediatric Gastroesophageal Reflux (GER) vs. Reflux Disease (GERD)

Gastroesophageal reflux (GER) is the involuntary retrograde movement of gastric contents into the esophagus, with or without regurgitation and vomiting. It is essential to distinguish benign physiological GER from pathological gastroesophageal reflux disease (GERD).

Physiological GER ('Happy Spitters')

• Epidemiology & Pathophysiology: Affects over 50% of all infants younger than 3 months of age. It stems from physiological immaturity of the lower esophageal sphincter (LES), characterized by frequent transient lower esophageal sphincter relaxations (TLESRs), a short intra-abdominal esophagus, an obtuse angle of His, a high liquid diet volume relative to body weight (equivalent to an adult drinking 10 to 12 liters of fluid daily), and predominantly recumbent positioning.
• Natural History: Regurgitation typically peaks at 4 months of age and spontaneously resolves in 90% to 95% of infants by 12 months of age as the child attains upright posture, begins consuming solid foods, and the neuromuscular tone of the gastroesophageal junction matures.
• Clinical Presentation: The infant effortlessly regurgitates formula after feeds, yet remains cheerful, comfortable, feeds eagerly, and demonstrates normal neurodevelopment and excellent weight gain along their established growth percentiles ('happy spitters').
• Nursing Management: Caregiver education, reassurance, and conservative feeding guidance. Pharmacological acid suppression or prokinetic therapy is strictly not indicated.

Pathological GERD: Diagnostic Thresholds & Complications

GER becomes pathological GERD when the retrograde reflux of gastric contents provokes bothersome symptoms or objective clinical complications:

1. Failure to Thrive (FTT) & Poor Weight Gain: Significant downward deviation across growth percentiles caused by caloric loss from persistent large-volume regurgitation or conditioned feeding refusal and oral aversion.
2. Reflux Esophagitis: Acid-induced mucosal ulceration producing retrosternal burning pain (heartburn), irritability, inconsolable crying during or immediately following feedings, arching of the back during feeds, hematemesis, or occult blood loss precipitating refractory iron deficiency anemia.
3. Sandifer Syndrome: A rare, dramatic neurobehavioral manifestation of GERD characterized by paroxysmal dystonic neck contortions, lateral head tilting (torticollis), and severe hyperextension of the spine and neck (opisthotonos). These episodes characteristically occur during or within 30 minutes of feeding and are frequently misdiagnosed as infantile spasms, focal seizures, or dystonia. Sandifer syndrome represents a learned, involuntary neuromotor reflex that elongates the esophagus to relieve retrosternal burning pain and accelerate esophageal clearance.
4. Respiratory Complications: Chronic microaspiration or reflex vagal bronchospasm provoking nocturnal cough, wheezing, refractory reactive airway disease (asthma), stridor, recurrent aspiration pneumonias, and brief resolved unexplained events (BRUE) with central or obstructive apnea.

Conservative & Non-Pharmacological Management Protocols

+-------------------------------------------------------------------------+
|                 CONSERVATIVE INFANT GERD PROTOCOLS                      |
+-------------------------------------------------------------------------+
|  1. FEEDING MODIFICATIONS:                                              |
|     - Small, frequent feedings (avoids gastric overdistension)          |
|     - Thickened feeds: Add 1 tbsp dry infant cereal per oz formula      |
|       (with cross-cut nipple; increases density, reduces regurgitation) |
|     - 2- to 4-week trial of extensively hydrolyzed formula              |
|       (Cow's milk protein allergy mimics GERD in up to 40% of infants)  |
+-------------------------------------------------------------------------+
|  2. POSTURAL POSITIONING:                                               |
|     - Hold upright on caregiver shoulder for 30 to 45 minutes post-feed |
|     - STRICT CONTRAINDICATION: NEVER PLACE IN CAR SEATS OR SWINGS!       |
|       (Slumped posture increases intra-abdominal pressure & acid reflux)|
|     - SLEEP SAFETY MANDATE: ALWAYS FLAT SUPINE ON FIRM SURFACE          |
|       (Crib wedges/elevations contraindicated per AAP safe sleep rules) |
+-------------------------------------------------------------------------+

• Safety Alert on Car Seats: Placing an infant in a car seat, infant carrier, or mechanical swing after feeding is strictly contraindicated for reflux management. The semi-reclined, slumped posture flexes the abdominal wall, significantly elevates intra-abdominal pressure, and directly overcomes lower esophageal sphincter resistance, dramatically exacerbating reflux.
• Safe Sleep Alignment: In accordance with American Academy of Pediatrics (AAP) safe sleep guidelines, infants must always be placed to sleep completely flat on their back (supine) on a firm, flat sleep surface. Crib head elevation, positional wedges, sleep positioners, and prone sleeping are strictly prohibited due to the heightened risk of Sudden Infant Death Syndrome (SIDS) and accidental asphyxiation.

Pharmacotherapy & Surgical Interventions

• Histamine-2 Receptor Antagonists (H2RAs): Famotidine (0.5 to 1 mg/kg/day divided twice daily). Rapidly suppresses basal and meal-stimulated gastric acid secretion. Effective for mild esophagitis, but its clinical utility is limited by tachyphylaxis (rapid pharmacological tolerance developing within 2 to 6 weeks of continuous therapy).
• Proton Pump Inhibitors (PPIs): Omeprazole (0.7 to 1.5 mg/kg/day once daily), Lansoprazole, or Esomeprazole. First-line therapy for endoscopically verified erosive esophagitis and severe GERD refractory to conservative measures. PPIs inhibit the H+/K+-ATPase enzyme in gastric parietal cells, providing superior acid suppression without tachyphylaxis. Administer 30 minutes before the morning feed on an empty stomach.
  • Long-Term PPI Safety Warnings: Chronic acid suppression in infants disrupts gastric acid antimicrobial barrier function, significantly increasing the risk of community-acquired pneumonia, acute gastroenteritis (Clostridioides difficile), hypomagnesemia, and impaired intestinal absorption of calcium, iron, and vitamin B12.
• Prokinetic Agents: (e.g., Metoclopramide). Strongly discouraged in pediatric guidelines due to high adverse event profiles, including extrapyramidal movement disorders, tardive dyskinesia, and cardiac arrhythmias (QTc prolongation).
• Nissen Fundoplication: The surgical gold standard for intractable, life-threatening GERD. The gastric fundus is mobilized and wrapped 360 degrees circumferentially around the distal esophagus to create a competent anti-reflux valve. Reserved for severe reflux refractory to maximal medical therapy, persistent aspiration with chronic lung disease, recurrent cyanotic apnea, or severe failure to thrive, most commonly performed in neurologically impaired children concurrently with gastrostomy tube placement.

---

2. Celiac Disease (Gluten-Sensitive Enteropathy)

Celiac disease is a chronic, immune-mediated systemic autoimmune enteropathy triggered by the ingestion of dietary gluten in genetically susceptible individuals.

Immunogenetics & Molecular Pathophysiology

1. Genetic Susceptibility: Strongly linked to human leukocyte antigen (HLA) class II heterodimers HLA-DQ2 (present in ~90% to 95% of patients) and HLA-DQ8 (present in 5% to 10%). Individuals who test negative for both HLA-DQ2 and HLA-DQ8 have a negative predictive value approaching 99% for celiac disease.
2. The Ingested Trigger — Gliadin: Gluten is a protein composite found in wheat, barley, and rye. Its alcohol-soluble peptide fraction, gliadin, is uniquely rich in proline and glutamine residues, rendering it resistant to luminal enzymatic degradation by gastric acid, pepsin, and pancreatic proteases.
3. Deamidation by Tissue Transglutaminase: Indigestible gliadin peptides cross the intestinal epithelial barrier into the lamina propria. The ubiquitous enzyme tissue transglutaminase (tTG) deamidates neutral glutamine residues into negatively charged glutamic acid.
4. Immune Activation Cascade: Deamidated gliadin peptides fit with high affinity into the positively charged peptide-binding grooves of HLA-DQ2 and HLA-DQ8 molecules on antigen-presenting cells (dendritic cells and macrophages). This presents the antigen to CD4+ T-helper cells, triggering an intense release of pro-inflammatory cytokines (Interferon-gamma, Interleukin-15, Interleukin-21). Simultaneously, CD8+ cytotoxic intraepithelial lymphocytes are recruited to directly induce enterocyte apoptosis.
5. Histopathological Triad (Marsh Classification):
   • Villous Atrophy: Blunting, flattening, and total loss of the microscopic finger-like mucosal villi.
   • Crypt Hyperplasia: Deepening and hyperproliferation of the crypts of Lieberkühn.
   • Intraepithelial Lymphocytosis: Marked infiltration of CD8+ lymphocytes into the epithelial surface (>25 IELs per 100 enterocytes).

+-------------------------------------------------------------------------+
|                  CELIAC DISEASE HISTOPATHOLOGY CASCADE                  |
+-------------------------------------------------------------------------+
| Dietary Gluten Ingestion (Wheat, Barley, Rye)                           |
|   --> Indigestible Gliadin crosses mucosal barrier                      |
|   --> Tissue Transglutaminase (tTG) deamidates gliadin                  |
|   --> Deamidated gliadin binds HLA-DQ2 / HLA-DQ8 on APCs                |
|   --> CD4+ T helper activation + CD8+ cytotoxic intraepithelial recruit |
|   --> Enterocyte apoptosis & mucosal destruction                        |
|   --> Severe Villous Blunting, Crypt Hyperplasia & Lymphocytosis        |
|   --> Loss of brush-border absorptive surface area                      |
|   --> Profound generalized malabsorption of fats, vitamins, & minerals  |
+-------------------------------------------------------------------------+

Clinical Presentation: Classic Malabsorptive vs. Extraintestinal

• Typical / Classical Presentation: Symptoms typically emerge between 6 and 24 months of age, several months following the introduction of gluten-containing weaning cereals into the infant's diet:
  • Chronic watery or pasty diarrhea.
  • Steatorrhea: Pale, greasy, bulky, frothy, unformed stools that possess a foul, rancid odor, frequently floating or adhering tenaciously to the toilet bowl due to high unabsorbed fat content.
  • Anorexia, persistent nausea, and abdominal cramping.
  • Classic Physical Phenotype: Striking, protuberant 'potbelly' abdominal distension contrasting dramatically with marked proximal muscle wasting (especially prominent wasting of the gluteal buttocks, anterior thigh muscles, and shoulder girdle).
  • Deceleration of weight gain progressing to linear height stunting and severe failure to thrive.
• Extraintestinal Manifestations & Micronutrient Deficiencies:
  • Hematologic: Refractory microcytic hypochromic iron-deficiency anemia unresponsive to oral iron therapy (the proximal duodenum is the primary site of dietary iron absorption and the area of maximal villous destruction); coagulopathy, easy bruising, and petechiae (elevated PT/INR from fat-soluble vitamin K malabsorption).
  • Musculoskeletal: Osteopenia, osteoporosis, rickets, and pathological fractures (from chronic malabsorption of vitamin D and calcium).
  • Dental: Enamel hypoplasia and horizontal structural pitting of permanent dentition.
  • Oral: Recurrent, painful aphthous stomatitis (canker sores).
  • Dermatologic Hallmark: Dermatitis herpetiformis—a characteristic cutaneous manifestation characterized by intensely pruritic, grouped, symmetrical papulovesicular eruptions distributed over extensor surfaces (elbows, knees, buttocks, scalp, and upper back). Skin biopsy reveals granular IgA deposition in dermal papillae. Dermatitis herpetiformis clears completely with a gluten-free diet.
  • Celiac Crisis: A life-threatening medical emergency presenting in young children with explosive watery diarrhea, profound hypokalemia, hypoproteinemia with anasarca, severe metabolic acidosis, and hypovolemic cardiovascular shock, requiring urgent fluid resuscitation and intravenous corticosteroids.
• High-Risk Screening Populations: First-degree relatives (10% to 15% risk), Type 1 Diabetes Mellitus (4% to 10% co-prevalence), autoimmune thyroiditis, Down syndrome (Trisomy 21), Turner syndrome, Williams syndrome, and selective IgA deficiency.

Diagnostic Protocols & Cardinal Testing Rules

*******************************************************************************
*              CRITICAL TESTING RULES: CELIAC DISEASE DIAGNOSIS               *
*                                                                             *
*  1. NEVER INITIATE A GLUTEN-FREE DIET PRIOR TO DIAGNOSTIC TESTING!          *
*     Eliminating gluten allows duodenal villi to regenerate and antibody     *
*     titers to decline rapidly, producing FALSE-NEGATIVE RESULTS!             *
*                                                                             *
*  2. ALWAYS MEASURE TOTAL SERUM IgA ALONGSIDE tTG-IgA!                       *
*     Selective IgA deficiency is 10 to 15 times more common in celiac         *
*     patients. If IgA deficient, tTG-IgA is falsely negative; clinicians      *
*     must order tTG-IgG or Deamidated Gliadin Peptide IgG (DGP-IgG)!         *
*******************************************************************************

1. Serological Screening:
   • Anti-Tissue Transglutaminase IgA (anti-tTG IgA): The primary first-line screening test of choice (>95% sensitivity and specificity).
   • Total Serum IgA Level: Measured concurrently. If selective IgA deficiency is present (<0.2 g/L), the anti-tTG IgA test will be falsely negative. In such patients, IgG-based serology (anti-tTG IgG or DGP-IgG) must be utilized.
   • Anti-Endomysial Antibody (EMA-IgA): Extremely high specificity (approaching 99%), used as a secondary confirmatory antibody.
2. Definitive Gold-Standard Diagnosis: Upper gastrointestinal endoscopy (EGD) with multiple mucosal biopsies (at least 1 to 2 biopsies from the duodenal bulb and at least 4 biopsies from the second and third portions of the duodenum). Demonstrates the classic histological triad of blunted villi, elongated crypts, and intraepithelial lymphocytosis.

Lifelong gluten-free nutrition and individualized oats advice

• Strict Lifelong Elimination of Dietary Gluten: Even minute trace contamination (>20 parts per million [ppm]) triggers mucosal immune activation and enterocyte damage.
• Avoid wheat, barley, and rye; evaluate oats separately:
  • B – Barley (including malt, malt syrup, malt extract, malt flavoring, malt vinegar, and beer).
  • R – Rye.
  • Oats: Consider appropriately labeled gluten-free oats with the treating clinician/dietitian; cross-contact and individual intolerance require attention.
  • W – Wheat (including all botanical variants: spelt, farro, durum, semolina, kamut, bulgur, couscous, graham flour, einkorn, and emmer).
• Permitted Safe Gluten-Free Grains & Starches: Corn, Rice, Quinoa, Soy, Tapioca, Potato, Arrowroot, Buckwheat, Millet, Sorghum, Amaranth, and Teff.
• Hidden Sources of Gluten: Processed lunch meats, hot dogs, canned soups, commercial gravies, soy sauce (contains wheat; must use certified gluten-free tamari), salad dressings, candy, medications, lip balm, and children's modeling clay (Play-Doh, which contains wheat flour and carries hand-to-mouth ingestion risks in toddlers).
• Temporary Secondary Lactose Restriction: Because the intestinal brush-border enzyme lactase is located at the very tips of the microvilli, extensive villous atrophy causes profound secondary lactase deficiency. Dairy products may exacerbate diarrhea and cramping initially. Temporary lactose reduction may help a child with demonstrated intolerance; reassess rather than prescribing a fixed restriction for every child.

---

3. Pediatric Inflammatory Bowel Disease (IBD): Crohn Disease vs. Ulcerative Colitis

Pediatric Inflammatory Bowel Disease (IBD) comprises two major chronic, relapsing-remitting idiopathic inflammatory conditions of the gastrointestinal tract: Crohn Disease (CD) and Ulcerative Colitis (UC). Approximately 25% of all IBD diagnoses are established during childhood and adolescence, peaking between 10 and 18 years of age.

Comprehensive Comparative Phenotype: Crohn Disease vs. Ulcerative Colitis

Pediatric-Specific Impact: Growth Failure and Pubertal Delay

Linear growth failure, delayed skeletal maturation, and arrested puberty represent major pediatric hallmarks of IBD, particularly in Crohn disease. Up to 85% of children with Crohn disease exhibit linear growth failure prior to diagnosis:

• Pathophysiology of Growth Failure: Multifactorial etiology driven by chronic elevated pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6) that directly suppress circulating insulin-like growth factor 1 (IGF-1) and induce growth hormone insensitivity at the epiphyseal growth plates. This is compounded by chronic anorexia, malabsorption, and corticosteroid-induced growth stunting.
• Clinical Mandate: Regular monitoring of growth velocity (height velocity cm/year) and Tanner staging is mandatory. A drop in height velocity often serves as the sole early harbinger of pediatric Crohn disease recurrence before gastrointestinal symptoms emerge.

Extraintestinal Manifestations (EIMs)

Extraintestinal manifestations occur in 25% to 35% of pediatric IBD patients:

1. Musculoskeletal: Non-deforming peripheral arthritis (asymmetric, involving large lower extremity joints such as knees and ankles; parallels intestinal disease activity); axial arthropathy (ankylosing spondylitis and sacroiliitis; strongly linked to HLA-B27, runs a course independent of intestinal inflammation); osteopenia and osteoporosis.
2. Dermatologic:
   • Erythema Nodosum: Painful, tender, warm, erythematous subcutaneous nodules occurring predominantly over the anterior tibial surfaces. Parallels intestinal disease activity.
   • Pyoderma Gangrenosum: Rare, severe, rapidly progressive necrotic ulcerations with violaceous, undermined borders. Can occur independently of luminal disease activity.
3. Ophthalmic: Episcleritis (painless scleral erythema) and anterior uveitis / iritis (painful red eye with photophobia and blurred vision; requires urgent slit-lamp ophthalmologic evaluation to prevent permanent vision loss).
4. Hepatobiliary: Primary Sclerosing Cholangitis (PSC)—chronic cholestatic fibro-obliterative destruction of intra- and extrahepatic bile ducts. Strongly associated with ulcerative colitis. Manifests with elevated alkaline phosphatase and gamma-glutamyl transferase (GGT), confirmed via MRCP. Carries an exceptionally high risk of progressing to biliary cirrhosis, portal hypertension, and cholangiocarcinoma.

Evidence-Based Pharmacological & Nutritional Therapeutics

+-------------------------------------------------------------------------+
|               PEDIATRIC IBD THERAPEUTIC ESCALATION                      |
+-------------------------------------------------------------------------+
|  1. EXCLUSIVE ENTERAL NUTRITION (EEN):                                  |
|     - FIRST-LINE induction therapy in pediatric mild-moderate Crohn     |
|     - 100% daily calories via liquid formula for 6 to 8 weeks           |
|     - Equals/exceeds corticosteroids for mucosal healing; spares growth |
+-------------------------------------------------------------------------+
|  2. 5-AMINOSALICYLATES (5-ASA):                                         |
|     - Mesalamine (oral / rectal): First-line maintenance in UC          |
+-------------------------------------------------------------------------+
|  3. SYSTEMIC CORTICOSTEROIDS:                                           |
|     - Oral Prednisone / IV Methylprednisolone: ACUTE INDUCTION ONLY     |
|     - CONTRAINDICATED FOR MAINTENANCE (Causes severe growth failure)    |
+-------------------------------------------------------------------------+
|  4. IMMUNOMODULATORS:                                                   |
|     - 6-Mercaptopurine / Azathioprine: TPMT enzyme testing MANDATORY    |
|       prior to initiation to prevent fatal bone marrow suppression      |
+-------------------------------------------------------------------------+
|  5. BIOLOGIC ANTI-TNF THERAPY:                                          |
|     - Infliximab (IV) / Adalimumab (SubQ): Moderate-severe CD and UC    |
|     - MANDATORY SCREEN: Tuberculin skin test / QuantiFERON & Hep B      |
|       prior to first dose to prevent fatal disseminated TB activation   |
+-------------------------------------------------------------------------+

• Exclusive Enteral Nutrition (EEN): International pediatric gastroenterology guidelines (ESPGHAN and NASPGHAN) establish EEN as the first-line therapy for the induction of remission in children with active mild-to-moderate Crohn disease. The patient consumes 100% of their daily caloric and nutritional requirements via an elemental or polymeric liquid formula (taken orally or through a fine-bore nasogastric tube) for 6 to 8 weeks, with the complete exclusion of all solid foods. EEN demonstrates remission rates of 80% to 85% (comparable or superior to systemic corticosteroids), directly induces mucosal and histological healing, reverses growth stunting, and avoids the toxic side effects of steroids.
• Thiopurines (6-MP & Azathioprine): Used for maintenance of remission. Prior to starting thiopurines, thiopurine methyltransferase (TPMT) and NUDT15 genotype and enzyme activity must be measured. Patients with deficient TPMT activity cannot metabolize the drug, accumulating toxic 6-thioguanine nucleotides that cause catastrophic, fatal aplastic anemia and bone marrow suppression.
• Biologic Anti-TNF Agents (Infliximab & Adalimumab): Monoclonal antibodies targeting tumor necrosis factor-alpha. Indicated for moderate-to-severe refractory Crohn disease, fistulizing disease, severe ulcerative colitis, and profound growth failure. Pre-Treatment Screening Mandate: Prior to the first biologic infusion, the nurse must verify documentation of negative screening for latent tuberculosis (via TST/PPD or QuantiFERON-TB Gold) and Hepatitis B serology. Anti-TNF agents suppress granuloma integrity; administering them to a patient with latent TB triggers overwhelming, fatal disseminated tuberculosis and opportunistic fungal sepsis.
• Colorectal Cancer Surveillance: Patients with long-standing ulcerative colitis or extensive Crohn colitis have an exponentially heightened lifetime risk of colorectal adenocarcinoma. Routine surveillance colonoscopy with chromoendoscopy and targeted biopsies must be initiated 8 to 10 years following initial diagnosis, repeated every 1 to 2 years thereafter.

Oats and lactose clarification: Oats are not automatically equivalent to wheat, barley, and rye. Cross-contact is common; consider only appropriately labeled gluten-free oats with the clinician/dietitian, and monitor individual tolerance. Lactose restriction is based on symptoms and assessment, not a mandatory fixed interval for every child. NIDDK celiac nutrition guidance.